That DM coexists with HT and/or DL is well known. To clarify this association, using a specialist clinic database from 1989 to 2022, we analyzed data on 2,630 Japanese with DM at baseline aged ≥18 years and HbA1c ≥6.5% and/or glucose-lowering drug prescription. Factors related to remissions of HT and DL in DM patients also in remission during follow-up were studied. DM remission was defined as HbA1c <6.5% for 3 months after cessation of a glucose-lowering drug. Remission of HT was defined as SBP <130 mmHg and that of DL as HDLC and non-HDLC of ≥40 mg/dL and <150 mg/dL, respectively without any drug. In addition to DM remission, 495 (26%), 419 (26%), and 96 (8%) achieved remissions of HT, DL and both HT and DL, respectively (Fig). Baseline HbA1c was positively associated with HT or DL remission (p for trends= 0.02, <0.01) along with DM remission. Baseline body mass (BMI) index was inversely associated with all (HT, DL and DM) remissions (p for trends ≤0.01). Compared with BMI changes from -2.9 to 2.9%, BMI reductions were significantly associated with all remissions (p for trend ≤0.01). About 25% of participants achieved either HT or DL remission while only 8% achieved remission of both. Although BMI change was a common factor in all remissions, remission of HT in people with DM requires physiological approaches differing from weight loss.
L. Khin: None. K. Fujihara: None. E.D. Ferreira: None. W. Goto: None. Y. Yamashita: None. S. Kodama: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.
